Home News

First quarter 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Wed, 13/05/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020
ROVI signs a co-operation agreement for a clinical trial to study the efficacy and safety of bemiparin in patients hospitalised with pneumonia caused by COVID-19
ROVI signs a co-operation agreement for a clinical trial to study the efficacy...
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has signed a co-operation agreement with Fundación de Investigación HM Hospitales to fund a...
2 min
14/04/2020
ROVI informs on the impact of Covid 19 on the company’s activities
ROVI informs on the impact of Covid 19 on the company’s activities
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) reports that, since the beginning of the spread of Covid-19, the company has been executing...
6 min
02/04/2020